Ascentage Pharma Group Internat
$25.65
0%
2026-04-22 10:12:13
www.ascentage.cn
NGM: AAPG
Explore Ascentage Pharma Group Internat stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$18.58 B
Current Price
$25.65
52W High / Low
$95.35 / $36.5
Stock P/E
—
Book Value
$0.52
Dividend Yield
—
ROCE
-25.48%
ROE
-1.55%
Face Value
—
EPS
—
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
767
Beta
0.81
Debt / Equity
148.38
Current Ratio
1.79
Quick Ratio
1.26
Forward P/E
-21.2
Price / Sales
4.22
Enterprise Value
$8.91 B
EV / EBITDA
-7.87
EV / Revenue
15.52
Rating
Strong Buy
Target Price
$49.14
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Erasca, Inc. | $21.71 | — | $5.91 B | — | -35.74% | -33.27% | $19.78 / $1.06 | $1.14 |
| 2. | Neumora Therapeutics, Inc. | $2.19 | — | $391.39 M | — | -152.06% | -1.21% | $3.65 / $0.61 | $0.6 |
| 3. | BioMarin Pharmaceutical Inc. | $54.33 | 30.1 | $10.47 B | — | 5.99% | 5.94% | $66.28 / $50.76 | $31.65 |
| 4. | Day One Biopharmaceuticals, Inc. | $21.48 | — | $2.22 B | — | -28.56% | -22.74% | $21.49 / $5.63 | $4.28 |
| 5. | enGene Therapeutics Inc. | $8.53 | — | $571.42 M | — | -65% | -46.07% | $12.25 / $2.65 | $4.2 |
| 6. | Quince Therapeutics, Inc. | $1.27 | — | $22.33 M | — | -33.74% | -2.48% | $45.5 / $0.8 | $0.02 |
| 7. | Atea Pharmaceuticals, Inc. | $5.71 | — | $457.32 M | — | -65.67% | -44.34% | $6.45 / $2.46 | $3.52 |
Quarterly Results
Figures shown in M / B
| Sales |
|---|
| Operating Profit |
| Net Profit |
| EPS in Rs |
Profit & Loss
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Sales | 980.65 M | 221.98 M | 209.71 M | 27.91 M |
| Operating Profit | -369.73 M | -872.64 M | -849.81 M | -869.84 M |
| Net Profit | -405.43 M | -925.64 M | -882.92 M | -782.42 M |
| EPS in Rs | -4.34 | -9.92 | -9.46 | -8.38 |
Balance Sheet
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Total Assets | 2.62 B | 2.5 B | 2.83 B | 2.94 B |
| Total Liabilities | 2.34 B | 2.43 B | 2.42 B | 1.71 B |
| Equity | 264.19 M | 60.42 M | 408.66 M | 1.23 B |
| Current Assets | 1.47 B | 1.34 B | 1.64 B | 1.89 B |
| Current Liabilities | 1.17 B | 934.17 M | 881.15 M | 361.11 M |
Cash Flow
Last available yearly cash flow history
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Operating CF | -111.36 M | -726.08 M | -653.91 M | -604.68 M |
| Investing CF | -362.04 M | 21.92 M | -384.61 M | -466.52 M |
| Financing CF | 314.77 M | 368.75 M | 619.27 M | 1.78 B |
| Free CF | -135.65 M | -782.92 M | -890.88 M | -1.04 B |
| Capex | -24.29 M | -56.84 M | -236.96 M | -436.63 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 341.77% | 5.85% | 651.38% | — |
| Earnings Growth % | 56.2% | -4.84% | -12.84% | — |
| Profit Margin % | -41.34% | -416.98% | -421.02% | -2803.38% |
| Operating Margin % | -37.7% | -393.11% | -405.23% | -3116.57% |
| Gross Margin % | 97.03% | 86.24% | 89.51% | 88.08% |
| EBITDA Margin % | -24.23% | -334.98% | -367.87% | -2820.47% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.